Eric Ross was listening to a popular psychiatry podcast one day last spring when “some pretty remarkable” research findings caught his attention.
A team of researchers in Egypt had shown that adding a cheap diabetes drug—metformin—to antidepressant therapy nearly doubled the treatment’s efficacy in people with moderate to severe depression. That meant the drug worked better than electric shock therapy, an option when antidepressants fail. It was a breakthrough.
“I thought, you know, wow, this is something that I’m comfortable prescribing that could make a huge difference for my patients,” said Ross, who at the time was doing his residency in psychiatry at Massachusetts General Hospital.
But when he looked up the study, he discovered several oddities. For instance, the number of patients who experienced an adverse event differed by exactly one for 17 out of 18 single events like fatigue or bloating. That seemed unlikely to have occurred by chance. And all of the scores of statistical tests the authors had done turned out just the way they would have wanted, a dream that rarely comes true in biomedical sciences.
Continue reading ‘I was fired up’: Psychiatrist effort prompts retraction of antidepressant treatment paper